APMD
Apnimed, Inc. (APMD) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (A+); its weakest is Growth (D-). The rating has held at C+ for 6 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | B- (3.0) | D- (0.7) | A+ (4.8) | D (1.5) | C+ (2.6) | C+ (2.5) |
| 2026-11-10 | B- (3.0) | F (0.7) | A+ (4.8) | D+ (1.8) | C+ (2.6) | C+ (2.6) |
| 2026-11-03 | B- (3.0) | F (0.7) | A+ (4.8) | C- (1.9) | C+ (2.7) | C+ (2.6) |
| 2026-10-27 | B- (2.9) | F (0.7) | A+ (4.8) | C- (2.0) | C+ (2.6) | C+ (2.6) |
| 2026-10-20 | B- (3.0) | F (0.7) | A+ (4.8) | C (2.5) | C+ (2.6) | C+ (2.7) |